Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cetuximab |
| Synonyms | |
| Therapy Description |
Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cetuximab | Erbitux | IMC-C225 | EGFR Antibody 60 | Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NRAS Q61X | colorectal cancer | resistant | Cetuximab | FDA contraindicated | Actionable | Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 3, codon 61 mutations is contraindicated (FDA.gov). | detail... |
| PIK3CA E542V | colorectal cancer | predicted - sensitive | Cetuximab | Case Reports/Case Series | Actionable | In a retrospective analysis, Erbitux (cetuximab) treatment resulted in stable disease in a colorectal carcinoma patient harboring a PIK3CA E542V mutation (PMID: 25714871). | 25714871 |
| CTNNB1 S33P | colorectal cancer | resistant | Cetuximab | Preclinical - Cell culture | Actionable | In a preclinical study, a colorectal cancer cell line expressing CTNNB1 S33P was resistant to treatment with Erbitux (cetuximab) in culture (PMID: 33574948). | 33574948 |
| PIK3CA H1047R | colorectal cancer | sensitive | Cetuximab | Case Reports/Case Series | Actionable | In a retrospective analysis, Erbitux (cetuximab) combined with radiation therapy resulted in stable disease for 6 months in a colorectal carcinoma patient harboring a PIK3CA H1047R mutation (PMID: 25714871). | 25714871 |
| NRAS exon4 | rectum cancer | resistant | Cetuximab | Guideline | Actionable | Erbitux (cetuximab) is not indicated for use in rectum cancer patients with NRAS exon 4 mutations (NCCN.org). | detail... |
| CTNNB1 S45F | colorectal cancer | resistant | Cetuximab | Preclinical - Cell culture | Actionable | In a preclinical study, a colorectal cancer cell line expressing CTNNB1 S45F was resistant to treatment with Erbitux (cetuximab) in culture (PMID: 33574948). | 33574948 |
| NRAS exon3 | rectum cancer | resistant | Cetuximab | Guideline | Actionable | Erbitux (cetuximab) is not indicated for use in rectum cancer patients with NRAS exon 3 mutations (NCCN.org). | detail... |
| BRAF class 2 | colorectal cancer | decreased response | Cetuximab | Clinical Study | Actionable | In a clinical study, colorectal cancer patients harboring class 2 BRAF mutations demonstrated a decreased response to treatment with the combination of either Erbitux (cetuximab) or Vectibix (panitumumab) plus chemotherapy compared to those with class 3 BRAF mutations, with a response rate of 8% (1/12) vs 50% (14/28) (P=0.02), respectively, in first, second, third or later-line setting and a response rate of 17% (1/6) vs 78% (7/9) (P=0.04), respectively, in the first or second-line setting (PMID: 31515458). | 31515458 |
| MAP2K1 K57T | colorectal cancer | predicted - resistant | Cetuximab | Case Reports/Case Series | Actionable | In a clinical case study, a patient with colorectal cancer developed liver metastases harboring MAP2K1 K57T that were insensitive to Erbitux (cetuximab) treatment and the mutation was confirmed to cause resistance in human colorectal cancer cell lines in culture (PMID: 26644315). | 26644315 |
| NRAS exon3 | colon cancer | resistant | Cetuximab | Guideline | Actionable | Erbitux (cetuximab) is not indicated for use in colon cancer patients with NRAS exon 3 mutations (NCCN.org). | detail... |
| BRAF G469A | colorectal cancer | not predictive | Cetuximab | Case Reports/Case Series | Actionable | In a clinical study, Erbitux (cetuximab) treatment as a third-line therapy resulted in stable disease with progression-free survival of 2.8 months in a patient with metastatic colorectal cancer harboring BRAF G469A (PMID: 31515458). | 31515458 |
| NRAS exon2 | colorectal cancer | resistant | Cetuximab | Guideline | Actionable | Erbitux (cetuximab) is not indicated for use in metastatic colorectal cancer patients with NRAS exon 2 mutations (PMID: 36307056; ESMO.org). | 36307056 detail... |
| BRAF V600E PIK3CA P449T | colorectal cancer | resistant | Cetuximab | Preclinical | Actionable | In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391). | 25838391 |
| BRAF V600E | colorectal cancer | resistant | Cetuximab | Guideline | Actionable | Erbitux (cetuximab), as a monotherapy, is not indicated for use in metastatic colorectal cancer patients with BRAF V600E (PMID: 36307056; ESMO.org). | 36307056 detail... |
| NRAS wild-type | rectum cancer | predicted - sensitive | Cetuximab | Guideline | Actionable | Erbitux (cetuximab), alone and in combination with chemotherapy, is included in guidelines for patients with advanced or metastatic rectal cancer that is BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). | detail... |
| CTNNB1 T41A | colorectal cancer | resistant | Cetuximab | Preclinical - Cell culture | Actionable | In a preclinical study, a colorectal cancer cell line expressing CTNNB1 T41A was resistant to treatment with Erbitux (cetuximab) in culture (PMID: 33574948). | 33574948 |
| BRAF wild-type | rectum cancer | predicted - sensitive | Cetuximab | Guideline | Actionable | Erbitux (cetuximab), alone and in combination with chemotherapy, is included in guidelines for patients with advanced or metastatic rectal cancer that is BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). | detail... |
| MAP2K1 F53L | colorectal cancer | resistant | Cetuximab | Preclinical - Cell culture | Actionable | In a preclinical study, expression of MAP2K1 F53L conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366). | 28179366 |
| BRAF G466V | colorectal cancer | sensitive | Cetuximab | Preclinical - Pdx | Actionable | In a preclinical study, treatment with Erbitux (cetuximab) reduced ERK signaling and resulted in tumor regression in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719). | 28783719 |
| BRAF G466V | colorectal cancer | sensitive | Cetuximab | Preclinical - Pdx | Actionable | In a preclinical study, Erbitux (cetuximab) treatment inhibited Erk signaling and reduced tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring BRAF G466V (PMID: 30559419). | 30559419 |
| BRAF T599dup | colorectal cancer | resistant | Cetuximab | Preclinical - Pdx | Actionable | In preclinical study, a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF T599dup was resistant to Erbitux (cetuximab) treatment (PMID: 31515458). | 31515458 |
| NRAS exon2 | colon cancer | resistant | Cetuximab | Guideline | Actionable | Erbitux (cetuximab) is not indicated for use in colon cancer patients with NRAS exon 2 mutations (NCCN.org). | detail... |
| NRAS Q61K | colon cancer | resistant | Cetuximab | Preclinical - Cell culture | Actionable | In a preclinical study, a colon cancer cell line expressing NRAS Q61K was resistant to Erbitux (cetuximab) in culture (PMID: 27636997). | 27636997 |
| PTEN positive | head and neck squamous cell carcinoma | predicted - sensitive | Cetuximab | Clinical Study - Cohort | Actionable | In a clinical study, high PTEN expression was associated with improved progression-free survival (HR=0.35, p=0.008) in head and neck squamous cell carcinoma patients treated with Erbitux (cetuximab) with or without Nexavar (sorafenib) (PMID: 30926065). | 30926065 |
| BRAF D594N | colorectal cancer | not predictive | Cetuximab | Preclinical - Pdx | Actionable | In a preclinical study, Erbitux (cetuximab) treatment inhibited tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF D594N (PMID: 31515458). | 31515458 |
| NRAS A59X | colorectal cancer | resistant | Cetuximab | FDA contraindicated | Actionable | Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 3, codon 59 mutations is contraindicated (FDA.gov). | detail... |
| NRAS exon4 | colon cancer | resistant | Cetuximab | Guideline | Actionable | Erbitux (cetuximab) is not indicated for use in colon cancer patients with NRAS exon 4 mutations (NCCN.org). | detail... |
| NRAS wild-type | colon cancer | predicted - sensitive | Cetuximab | Guideline | Actionable | Erbitux (cetuximab), alone and in combination with chemotherapy, is included in guidelines for patients with advanced or metastatic colon cancer that is BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). | detail... |
| NRAS K135N | colorectal cancer | predicted - sensitive | Cetuximab | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a cell line xenograft model of colorectal cancer expressing NRAS K135N demonstrated similar sensitivity to Erbitux (cetuximab) treatment compared to a NRAS wild-type model (PMID: 34117033). | 34117033 |
| MAP2K1 C121S | colorectal cancer | resistant | Cetuximab | Preclinical - Cell culture | Actionable | In a preclinical study, expression of MAP2K1 C121S conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366). | 28179366 |
| BRAF K601E | colorectal cancer | resistant | Cetuximab | Preclinical - Pdx | Actionable | In preclinical study, a colorectal patient-derived xenograft (PDX) model harboring BRAF K601E was resistant to Erbitux (cetuximab) treatment (PMID: 31515458). | 31515458 |
| BRAF K601E | colorectal cancer | resistant | Cetuximab | Preclinical - Pdx | Actionable | In a preclinical study, Erbitux (cetuximab) treatment did not inhibit Erk signaling or reduce tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring BRAF K601E (PMID: 30559419). | 30559419 |
| BRAF V600E | colon cancer | resistant | Cetuximab | Guideline | Actionable | Erbitux (cetuximab), as a monotherapy, is not indicated for use in colon cancer patients with BRAF V600E (NCCN.org). | detail... |
| BRAF L525R | colorectal cancer | not predictive | Cetuximab | Case Reports/Case Series | Actionable | In a clinical study, Erbitux (cetuximab) treatment as a third-line therapy resulted in stable disease with progression-free survival of 4 months in a patient with metastatic colorectal cancer harboring BRAF L525R (PMID: 31515458). | 31515458 |
| NRAS G12V | colorectal cancer | resistant | Cetuximab | Preclinical - Cell culture | Actionable | In a preclinical study, colorectal cancer cells harboring NRAS G12V demonstrated resistance to Erbitux (cetuximab) in culture (PMID: 28179366). | 28179366 |
| NRAS exon4 | colorectal cancer | resistant | Cetuximab | Guideline | Actionable | Erbitux (cetuximab) is not indicated for use in metastatic colorectal cancer patients with NRAS exon 4 mutations (PMID: 36307056; ESMO.org). | 36307056 detail... |
| NRAS G12X | colorectal cancer | resistant | Cetuximab | FDA contraindicated | Actionable | Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 2, codon 12 mutations is contraindicated (FDA.gov). | detail... |
| NRAS exon3 | colorectal cancer | resistant | Cetuximab | Guideline | Actionable | Erbitux (cetuximab) is not indicated for use in metastatic colorectal cancer patients with NRAS exon 3 mutations (PMID: 36307056; ESMO.org). | 36307056 detail... |
| BRAF V600E | rectum cancer | resistant | Cetuximab | Guideline | Actionable | Erbitux (cetuximab), as a monotherapy, is not indicated for use in rectum cancer patients with BRAF V600E (NCCN.org). | detail... |
| NRAS K117X | colorectal cancer | resistant | Cetuximab | FDA contraindicated | Actionable | Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 4, codon 117 mutations is contraindicated (FDA.gov). | detail... |
| NRAS A146X | colorectal cancer | resistant | Cetuximab | FDA contraindicated | Actionable | Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 4, codon 146 mutations is contraindicated (FDA.gov). | detail... |
| PIK3CA mutant | cervical cancer | decreased response | Cetuximab | Phase II | Actionable | In a Phase II clinical trial, Erbitux (cetuximab) treatment, in addition to radiochemotherapy, did not result in any complete responses (0/8) and demonstrated a worse disease free survival when compared to radiochemotherapy alone in cervical cancer patients harboring PIK3CA mutations (PMID: 25724520). | 25724520 |
| NRAS exon2 | rectum cancer | resistant | Cetuximab | Guideline | Actionable | Erbitux (cetuximab) is not indicated for use in rectum cancer patients with NRAS exon 2 mutations (NCCN.org). | detail... |
| PIK3CA H1047R | head and neck squamous cell carcinoma | resistant | Cetuximab | Preclinical - Cell culture | Actionable | In a preclinical study, head and neck squamous cell carcinoma cells harboring PIK3CA H1047R were resistant to Erbitux (cetuximab) in culture (PMID: 30962319). | 30962319 |
| MAP2K1 K57N | colorectal cancer | resistant | Cetuximab | Preclinical | Actionable | In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Erbitux (cetuximab) in culture (PMID: 26644315). | 26644315 |
| NRAS G13X | colorectal cancer | resistant | Cetuximab | FDA contraindicated | Actionable | Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 2, codon 13 mutations is contraindicated (FDA.gov). | detail... |
| HRAS G12V | Advanced Solid Tumor | resistant | Cetuximab | Preclinical | Actionable | In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 22797062). | 22797062 |
| NRAS G115Efs*46 | colorectal cancer | predicted - resistant | Cetuximab | Clinical Study - Cohort | Actionable | In a retrospective analysis, NRAS G115Efs*46 was identified at a frequency of >1% in 3 of 23 patients with metastatic colorectal cancer who did not respond to anti-EGFR therapy (Erbitux (cetuximab), n=12 or Vectibix (panitumumab), n=11), and was associated with a lack of response (p=0.029) to EGFR-targeted therapy (PMID: 32796636). | 32796636 |
| BRAF wild-type | colon cancer | predicted - sensitive | Cetuximab | Guideline | Actionable | Erbitux (cetuximab), alone and in combination with chemotherapy, is included in guidelines for patients with advanced or metastatic colon cancer that is BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). | detail... |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01238237 | Phase I | Cetuximab | Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma | Completed | USA | 0 |
| NCT01663259 | Phase I | Cetuximab | Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients | Completed | USA | 0 |
| NCT01001377 | Phase III | Cetuximab Panitumumab | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | Completed | USA | SWE | SVK | ROU | POL | NLD | LVA | LTU | ITA | ISR | GBR | FRA | CZE | CAN | BGR | BEL | AUS | 12 |
| NCT04587128 | Phase II | Cetuximab Cetuximab + Irinotecan Panitumumab Irinotecan + Panitumumab | Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | Recruiting | USA | 0 |
| NCT04375384 | Phase II | Cetuximab | Study to Evaluate Effect of Cetuximab Given as Single Agent After Immunotherapy | Recruiting | USA | 0 |
| NCT00956007 | Phase III | Cetuximab | Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer | Active, not recruiting | USA | CAN | 2 |
| NCT02358031 | Phase III | Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin | A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) | Completed | 0 | |
| NCT01309126 | Phase III | Cetuximab Cetuximab + PGG beta-glucan | Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer | Terminated | USA | FRA | DEU | 1 |
| NCT01744340 | Phase Ib/II | Eribulin Cetuximab | A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer | Completed | USA | 0 |
| NCT01652482 | Phase II | Cetuximab Duligotuzumab Fluorouracil + Irinotecan + Leucovorin | A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | Completed | USA | ROU | NZL | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 0 |
| NCT01218048 | Phase II | Cisplatin Carboplatin Cetuximab | ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
| NCT01467115 | Phase II | Leucovorin Cisplatin + Docetaxel + Fluorouracil Filgrastim Cetuximab | INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER | Completed | USA | 0 |
| NCT04117945 | Phase II | Regorafenib Irinotecan + Panitumumab Panitumumab Cetuximab + Irinotecan Cetuximab | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
| NCT04590963 | Phase III | Cetuximab Cetuximab + Monalizumab | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1) | Active, not recruiting | USA | POL | NLD | ITA | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 6 |
| NCT04008030 | Phase III | Nivolumab Fluorouracil + Irinotecan + Leucovorin Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab Ipilimumab + Nivolumab | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW) | Recruiting | USA | TUR | ROU | NOR | NLD | ITA | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
| NCT04853043 | Phase II | Cetuximab | Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer | Terminated | USA | 0 |
| NCT00904345 | Phase II | Cetuximab | Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) | Terminated | USA | 0 |
| NCT01979211 | Phase II | Cetuximab | Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck | Completed | USA | 0 |
| NCT05930938 | Phase III | Cetuximab Cetuximab + Xevinapant | Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer (XXL_2022-01) | Suspended | FRA | 0 |
| NCT02057107 | Phase II | Cetuximab Docetaxel | Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Completed | USA | 0 |
| NCT06496178 | Phase III | Methotrexate Cetuximab Docetaxel MCLA-158 | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients | Recruiting | USA | ISR | AUS | ARG | 3 |
| NCT03349710 | Phase III | Cetuximab Cisplatin Cetuximab + Nivolumab Cisplatin + Nivolumab | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | Completed | USA | TUR | POL | ITA | FRA | ESP | 4 |
| NCT01468896 | Phase Ib/II | Cetuximab | Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
| NCT02499120 | Phase II | Palbociclib Cetuximab | Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer | Completed | USA | SVK | ROU | POL | ITA | HUN | ESP | CZE | 7 |
| NCT03416153 | Phase II | Cetuximab | Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer | Active, not recruiting | USA | 0 |
| NCT02281955 | Phase II | Cisplatin Carboplatin Cetuximab | De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC | Active, not recruiting | USA | 0 |
| NCT01910610 | Phase III | Cetuximab Irinotecan + Panitumumab Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine + Oxaliplatin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1) | Active, not recruiting | ISR | IRL | FRA | 0 |
| NCT03769311 | Phase II | Cetuximab | Cetuximab in Head and Neck Cancer Patients | Completed | USA | 0 |
| NCT04189055 | Phase II | Cetuximab + Irinotecan Cetuximab | Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (CETIDYL) | Recruiting | FRA | 0 |
| NCT05725200 | Phase II | Dasatinib Palbociclib Gemcitabine Trastuzumab Cetuximab Pertuzumab Panobinostat Alectinib Venetoclax Larotrectinib Encorafenib Everolimus Idelalisib Crizotinib Pembrolizumab Methotrexate Talazoparib | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer (EVIDENT) | Recruiting | NOR | 0 |
| NCT04065555 | Phase I | Avelumab + Subasumstat Cetuximab Cetuximab + Subasumstat Subasumstat Avelumab | Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | Completed | USA | 0 |
| NCT05226871 | Phase II | Letrozole + Palbociclib Cetuximab + Palbociclib Cetuximab Fulvestrant + Palbociclib | Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies | Recruiting | USA | 6 |
| NCT03769506 | Phase III | Methotrexate Cetuximab ASP-1929 Docetaxel Paclitaxel | ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy | Recruiting | USA | 3 |
| NCT01472016 | Phase I | Docetaxel ABT-700 Cetuximab Erlotinib Fluorouracil + Irinotecan + Leucovorin | Study of ABT-700 in Subjects With Advanced Solid Tumors | Completed | 0 | |
| NCT02324608 | Phase I | Cetuximab | Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer | Completed | USA | 0 |
| NCT01524978 | Phase II | Vemurafenib Cetuximab | A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers | Completed | USA | GBR | FRA | ESP | DEU | 1 |
| NCT02105636 | Phase III | Methotrexate Cetuximab Docetaxel Nivolumab | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BRA | ARG | 4 |
| NCT05041127 | Phase II | Cetuximab | Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma | Recruiting | USA | 0 |
| NCT01285037 | Phase I | Cisplatin Cetuximab Merestinib | A Study of LY2801653 in Advanced Cancer | Completed | USA | 0 |
| NCT02252042 | Phase III | Pembrolizumab Methotrexate Cetuximab Docetaxel | Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) | Completed | 0 | |
| NCT01816984 | Phase Ib/II | Cetuximab Buparlisib | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Completed | USA | 0 |
| NCT01577173 | Phase II | Cetuximab Duligotuzumab | A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck | Completed | USA | ROU | ITA | HUN | GBR | FRA | ESP | DEU | BGR | BEL | AUS | 0 |
| NCT04966481 | Phase III | Cetuximab + Palbociclib Cetuximab | Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor | Recruiting | USA | 0 |
| NCT03258554 | Phase II | Cetuximab Durvalumab | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin | Active, not recruiting | USA | CAN | 0 |
| NCT00957853 | Phase II | Cetuximab Cixutumumab | Preoperative Treatment With Cetuximab and/or IMC-A12 | Completed | USA | 0 |
| NCT04892173 | Phase III | Cetuximab NBTXR3 | NBTXR3 With or Without Cetuximab in LA-HNSCC | Recruiting | USA | SWE | ROU | ISR | HUN | HRV | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | 9 |
| NCT02124850 | Phase I | Cetuximab | A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX® (Cetuximab) and VTX-2337 | Terminated | USA | 0 |
| NCT03727061 | Phase II | Cisplatin + Fluorouracil Carboplatin + Fluorouracil Pembrolizumab Cetuximab Nivolumab | Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer | Active, not recruiting | USA | 0 |
| NCT03693612 | Phase Ib/II | GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab | GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | Completed | USA | CAN | AUS | 0 |
| NCT01025089 | Phase II | Cetuximab Cisplatin + Cyclophosphamide + Doxorubicin | Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma | Active, not recruiting | USA | 0 |
| NCT01104922 | Phase II | Cetuximab | Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck | Completed | USA | 0 |
| NCT05291156 | Phase II | Cetuximab Avelumab + Cetuximab | CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy | Recruiting | ITA | 0 |
| NCT06447987 | Phase I | Cetuximab Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells Cyclophosphamide + Fludarabine | Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
| NCT00292955 | Phase II | Cetuximab Cisplatin | Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma | Unknown status | USA | 0 |
| NCT03387111 | Phase Ib/II | Capecitabine Nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab Nogapendekin alfa inbakicept Fluorouracil ETBX-011 | Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy | Terminated | USA | 0 |
| NCT02800486 | Phase II | Cetuximab | Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA | Recruiting | USA | 0 |
| NCT02555644 | Phase I | Prexasertib Cisplatin Cetuximab | A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer | Completed | USA | FRA | 0 |
| NCT04428151 | Phase II | Lenvatinib + Pembrolizumab Docetaxel Paclitaxel Capecitabine Cetuximab Lenvatinib | Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) | Active, not recruiting | USA | ROU | NOR | ISR | GBR | FRA | ESP | DNK | CAN | BRA | AUS | 4 |
| NCT06064877 | Phase III | Cetuximab + Ficlatuzumab Cetuximab | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN) | Recruiting | USA | GBR | CAN | AUS | 2 |
CKB BOOST